WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406179
CAS#: 1883548-83-1 (2HCl)
Description: BS-181 is a highly selective CDK inhibitor for CDK7 with an IC(50) of 21 nmol/L. Testing of other CDKs as well as another 69 kinases showed that BS-181 only inhibited CDK2 at concentrations lower than 1 micromol/L, with CDK2 being inhibited 35-fold less potently (IC(50) 880 nmol/L) than CDK7. In MCF-7 cells, BS-181 inhibited the phosphorylation of CDK7 substrates, promoted cell cycle arrest and apoptosis to inhibit the growth of cancer cell lines, and showed antitumor effects in vivo.
MedKoo Cat#: 406179
Name: BS-181 HCl
CAS#: 1883548-83-1 (2HCl)
Chemical Formula: C22H34Cl2N6
Exact Mass:
Molecular Weight: 453.46
Elemental Analysis: C, 58.27; H, 7.56; Cl, 15.64; N, 18.53
BS-181 HCl, purity > 98%, is in stock.The same day shipping after order is received.
Related CAS #: 1092443-52-1 (free base) 1883548-83-1 (2HCl) 1397219-81-6 (HCl)
Synonym: BS181; BS-181; BS 181; BS-181 HCl; BS-181 hydrochloride.
IUPAC/Chemical Name: N5-(6-aminohexyl)-N7-benzyl-3-isopropylpyrazolo[1,5-a]pyrimidine-5,7-diamine dihydrochloride
InChi Key: XYXAMTBYYTXHSO-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H32N6.2ClH/c1-17(2)19-16-26-28-21(25-15-18-10-6-5-7-11-18)14-20(27-22(19)28)24-13-9-4-3-8-12-23;;/h5-7,10-11,14,16-17,25H,3-4,8-9,12-13,15,23H2,1-2H3,(H,24,27);2*1H
SMILES Code: CC(C1=C2N=C(NCCCCCCN)C=C(NCC3=CC=CC=C3)N2N=C1)C.[H]Cl.[H]Cl
The following data is based on the product molecular weight 453.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Ali S, Heathcote DA, Kroll SH, Jogalekar AS, Scheiper B, Patel H, Brackow J, Siwicka A, Fuchter MJ, Periyasamy M, Tolhurst RS, Kanneganti SK, Snyder JP, Liotta DC, Aboagye EO, Barrett AG, Coombes RC. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res. 2009 Aug 1;69(15):6208-15. doi: 10.1158/0008-5472.CAN-09-0301. Epub 2009 Jul 28. PubMed PMID: 19638587; PubMed Central PMCID: PMC2875168.
